



## Cancer Immunotherapy: Advances and Future Prospects

Guest Editor:

**Dr. Sumit Agarwal**

Department of Pathology,  
University of Alabama at  
Birmingham, Birmingham, AL  
35294, USA

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

In this special issue, the journal will focus on Cancer Immunotherapy, its advances and future prospects. The knowledge gained in the field of cancer immunotherapy is now being applied to unleash a robust immune response against tumors after years of painstaking research. This lead to better understand the interaction between tumors and the host immune system. However, challenges still exist in this field, includes better predicting patients response to therapy, finding targets for treatment of tumors lacking tumor-infiltrating lymphocytes also called as “immunologically cold tumors” and enhancing immunotherapy strategies by customizing immunotherapy approaches for each biological subtype. Therefore, we would like to have this special issue based on recent advances in the understanding of cancer and different immunotherapies. Adding new information on these subjects and addressing challenges and questions addressed above may lead to a better understanding of the immune response against cancer and may aid in developing cancer immunotherapies.

Dr. Sumit Agarwal

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)